Loading...

PE anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PE_083106
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
  • H1dot2F3_PE_083106
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104507 50 µg 98€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104508 200 µg 235€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  2. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  3. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  4. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  5. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  6. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  7. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  8. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  9. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  10. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  11. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  12. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  13. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  14. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  15. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  16. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  17. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  18. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  19. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  20. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  21. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  22. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  23. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  24. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  25. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  26. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  27. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  28. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  29. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  30. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  31. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  32. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  33. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  34. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  35. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  36. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  37. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  38. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  39. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  40. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  41. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  42. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  43. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  44. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  45. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  46. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  47. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  48. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  49. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  50. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  51. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  52. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  53. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  54. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  55. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  56. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  57. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  58. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  59. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  60. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  61. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  62. Lopes N, et al. 2022. Elife. 11:. PubMed
  63. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  64. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  65. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  66. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  67. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  68. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  69. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  70. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  71. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  72. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  73. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  74. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  75. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  76. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  77. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  78. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_313110 (BioLegend Cat. No. 104507)
AB_313111 (BioLegend Cat. No. 104508)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 4    Revision Date: 04/18/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account